East and North Hertfordshire NHS Trust
Welcome,         Profile    Billing    Logout  
 22 Trials 
26 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hoskin, Peter J
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
POPS, NCT02978014: A Trial Assessing Post-Operative Use of ProSpare, a Rectal Obturator in Prostate Cancer Radiotherapy

Recruiting
2
245
Europe
ProSpare, Rectal obturator
Royal Marsden NHS Foundation Trust, Institute of Cancer Research, United Kingdom
Cancer
12/24
12/24
Shaw, Heather S
EBIN, NCT03235245 / 2017-002887-42: Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

Active, not recruiting
2
271
Europe
Nivolumab + Ipilimumab, Encorafenib + Binimetinib
European Organisation for Research and Treatment of Cancer - EORTC
Unresectable Stage III Melanoma, Stage IV Melanoma
10/23
01/27
TebeMRD, NCT05315258: Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

Recruiting
2
850
Europe
Tebentafusp, IMCgp100
University of Oxford, Immunocore Ltd, Natera, Inc.
Melanoma (Skin), Melanoma, Uveal
06/25
06/26
SCOPE, NCT04079166: SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The Study)

Recruiting
2
130
Europe
SCIB1 or iSCIB1+ DNA vaccine
Scancell Ltd
Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV
01/26
01/26
IDE196-009, NCT05907954: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Recruiting
2
82
Europe, Canada, US, RoW
Darovasertib, IDE196, LXS196
IDEAYA Biosciences
Uveal Melanoma
01/26
01/29
NCT04785365: Long-Term Follow-Up Study of Patients Receiving ATL001

Terminated
2
1
Europe
Biological: ATL001
Achilles Therapeutics UK Limited
Melanoma, Advanced Non Small Cell Lung Cancer
10/23
10/23
IMC-F106C-101, NCT04262466 / 2019-004046-16: Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Recruiting
1/2
727
Europe, Canada, US, RoW
Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp, Brenetafusp and bevacizumab, Brenetafusp and kinase inhibitors
Immunocore Ltd
Select Advanced Solid Tumors
02/26
08/26
NVG111-101, NCT04763083 / 2020-000820-20: First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

Recruiting
1
90
Europe
NVG-111
NovalGen Ltd.
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non-small Cell Lung Cancer (NSCLC), Malignant Melanoma
12/23
12/25
OMNi, NCT04588662: A Prospective Natural History Study in Uveal Melanoma

Recruiting
N/A
700
Europe, Canada, US, RoW
Columbia University
Uveal Melanoma
07/26
07/26
Nathan, Paul
ATOM, NCT06246149: Adjuvant Tebentafusp in High Risk Ocular Melanoma

Not yet recruiting
3
290
NA
Tebentafusp
European Organisation for Research and Treatment of Cancer - EORTC, Northwell Health, Immunocore Ltd
Uveal Melanoma
11/32
11/32
NCT03223753: Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

Active, not recruiting
3
384
Canada, US
Educational Intervention, Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational, Internet-Based Intervention, Laboratory Biomarker Analysis, Medical Device Usage and Evaluation, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Children's Oncology Group, National Cancer Institute (NCI)
Carcinoma In Situ, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
03/25
03/25
ARST2031, NCT04994132: A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Recruiting
3
118
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Dactinomycin, Actinomycin A IV, Actinomycin C1, Actinomycin D, Actinomycin I1, Actinomycin IV, Actinomycin X 1, Actinomycin-[thr-val-pro-sar-meval], Cosmegen, DACT, Dactinomycine, Lyovac Cosmegen, Meractinomycin, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate, Vinorelbine Tartrate, Biovelbin, Eunades, KW 2307, KW-2307, KW2307, Navelbine, Navelbine Ditartrate, NVB, Vinorelbine Ditartrate, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
Children's Oncology Group, National Cancer Institute (NCI)
Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Metastatic Embryonal Rhabdomyosarcoma, Metastatic Rhabdomyosarcoma, Solid Alveolar Rhabdomyosarcoma, Spindle Cell Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma
09/27
09/27
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
420
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
NCT05529316: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Suspended
2
220
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034
Agenus Inc.
Advanced Melanoma
05/28
05/28
TebeMRD, NCT05315258: Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

Recruiting
2
850
Europe
Tebentafusp, IMCgp100
University of Oxford, Immunocore Ltd, Natera, Inc.
Melanoma (Skin), Melanoma, Uveal
06/25
06/26
NCT00082745: Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

Recruiting
N/A
3885
Europe, Canada, US, RoW
Laboratory Biomarker Analysis, Questionnaire Administration
Children's Oncology Group, National Cancer Institute (NCI)
Childhood Malignant Neoplasm
12/04
 
PRIMM, NCT03643289: Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and Metabolomics

Recruiting
N/A
450
Europe
East and North Hertfordshire NHS Trust, King's College London
Melanoma (Skin)
05/23
05/23
NCT03632343: The Pain Squad+ Smartphone App To Support Real-Time Pain Management for Adolescents With Cancer

Recruiting
N/A
222
Canada
Pain Squad+ with Nurse Support, Pain Squad+
The Hospital for Sick Children
Therapy-Associated Cancer
09/24
12/24
NCT05832138: ONLOOP Trial: Evaluating a New Surveillance and Support System for Survivors of Childhood Cancer in Ontario

Not yet recruiting
N/A
900
NA
ONLOOP program
The Hospital for Sick Children, Women's College Hospital, Ottawa Hospital Research Institute
Survivorship, Cancer, Heart Diseases, Secondary Cancer, Colorectal Cancer, Breast Cancer
09/25
10/26
NCT01120353: Childhood Cancer Survivor Study

Recruiting
N/A
50000
Canada, US
St. Jude Children's Research Hospital, National Cancer Institute (NCI), Fred Hutchinson Cancer Center, Nationwide Children's Hospital, M.D. Anderson Cancer Center, University of Southern California, Children's Hospital Medical Center, Cincinnati, University of California, San Francisco
Cancer
11/26
11/26
Hall, Marcia
CORINTH, NCT04046133: Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus

Recruiting
1b
50
Europe
Pembrolizumab, Radiotherapy, Chemotherapy (Mytomycin or Mitomycin and Capecitabine)
Cardiff University
Anal Cancer Stage III A, Anal Cancer Stage III B
11/22
11/22
VALTIVE1, NCT04523116: Validation of Tie2 as the First Tumour Vascular Response Biomarker for VEGF Inhibitors:

Recruiting
N/A
176
Europe
University of Manchester, Cancer Research UK, Centre for Trials Research, Cardiff University
Ovary Cancer
05/23
06/23
BriTROC-2, NCT05537844: Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma

Recruiting
N/A
250
Europe
Liz-Anne Lewsley, Ovarian Cancer Action
Ovarian Cancer, High Grade Serous Carcinoma, Carcinosarcoma, Ovarian, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, BRCA1 Mutation, BRCA2 Mutation
10/24
04/25
Alonzi, Roberto
ARPC-MRI, NCT03967080: Adaptive Radiotherapy for High-risk Prostate Cancer Using Multiparametric MRI

Recruiting
N/A
15
Europe
East and North Hertfordshire NHS Trust
Prostate Cancer
03/22
09/22
Fitzpatrick, Amanda
SCOPE, NCT04079166: SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The Study)

Recruiting
2
130
Europe
SCIB1 or iSCIB1+ DNA vaccine
Scancell Ltd
Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV
01/26
01/26

Download Options